

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 11, 2025

For Immediate Release

Kitazato Corporation
Futoshi INOUE
President and CEO

Announcement of Research Results on the Development of a New Oocyte Cryopreservation Technology

According to our research, Kitazato Corporation is the first company in the world to have developed the “One-Step Oocyte Vitrification Technology.” The research results were selected for an oral presentation at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2025, held in October 2025.

In this study, we developed a “One-Step Method” that allows multiple processes involved in oocyte cryopreservation to be completed in a single step. By employing newly formulated vitrification and warming solutions, this method achieved survival and developmental rates comparable to those of conventional multi-step protocols, while significantly reducing operation time and improving reproducibility. This new technology is expected to enhance efficiency, safety, and consistency in clinical laboratory practice, and is expected to pave the way for the automation of oocyte vitrification and warming procedures within the next two years. The study is currently in the clinical trial phase in collaboration with international partner facilities, and progress updates will be provided periodically.

Title: PRECLINICAL VALIDATION OF A NOVEL ONE-STEP PROTOCOL FOR OOCYTE VITRIFICATION

Authors: Futoshi INOUE, Ph.D., et al.

Abstract

OBJECTIVE: To assess the efficacy of a simplified one-step vitrification protocol for oocytes cryopreservation in terms of survival, developmental competence, and laboratory efficiency compared to the standard multi-step protocol.

MATERIALS AND METHODS: Omitted.

CONCLUSIONS: The novel one-step oocyte vitrification protocol demonstrates comparable survival, developmental, and full-term outcomes to standard protocols, while significantly reducing procedural complexity and handling time. These findings support its potential application in clinical ART settings, pending further validation in human oocytes.

IMPACT STATEMENT: The simplified one-step vitrification method has the potential to streamline oocyte cryopreservation in ART, improving consistency and reducing operator-dependent variability while maintaining high efficacy, thereby enhancing clinical and laboratory efficiency.